@article{8e8626c65c71496ebc63f64035bc1a7a,
title = "Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: An observational study",
abstract = "Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. Trial registration number: NCT0337077.",
keywords = "NSCLC, T790M, afatinib, osimertinib, sequential",
author = "Hochmair, {Maximilian J.} and Alessandro Morabito and Desiree Hao and Yang, {Cheng Ta} and Soo, {Ross A.} and Yang, {James C.H.} and Rasim Gucalp and Balazs Halmos and Lara Wang and Amanda Golembesky and Angela M{\"a}rten and Tanja Cufer",
note = "Funding Information: The authors thank the patients, their families, the investigators and staff who participated in the study. This work was supported by Boehringer Ingelheim. Contract Research Organization support was executed by Parexel. Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Lynn Pritchard and Jane Saunders of GeoMed, an Ashfield Company, part of UDG Healthcare plc, during the preparation of this article. There is no applicable grant number. Funding Information: This study was supported by Boehringer Ingelheim. MJ Hochmair reports personal fees from Speakers honorarium Boehringer Ingelheim, AstraZeneca, and Roche. A Morabito has received honoraria from Boehringer Ingelheim, Roche, AstraZeneca, Pfizer, MSD and Bristol Myers Squibb. D Hao reports research funding and consultancy from Boehringer Ingelheim and Astra Zeneca. RA Soo reports grants and personal fees from Astra Zeneca, personal fees from BMS, Boehringer Ingelheim, Celgene, Lilly, Merck, Novartis, Pfizer, Roche, Taiho and Ignyta. JC-H Yang reports personal fees from Boehringer Ingelheim, Eli Lilly, Roche/Genentech, Chugai, Astellas, MSD, Merck Serono, Pfizer, Novartis, Celgene, Merrimack, Yuhan Pharmaceuticals, Bristol Myers Squibb, Ono Pharmaceuticals, Daiichi Sankyo, AstraZeneca, Hansoh Pharmaceuticals and Takeda Pharmaceuticals. B Halmos reports grants and personal fees from Boehringer Ingelheim, Astra Zeneca, Pfizer, Novartis and Takeda, personal fees from Genentech/Roche and grants from Merck. L Wang, A Golembesky and A M{\"a}rten report employment with Boehringer Ingelheim, TC reports consultancy and honoraria from AstraZeneca, Roche, Pfizer, MSD, Bristol Myers Squibb and Boehringer Ingelheim. C-T Yang and R Gucalp report no competing interests. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: {\textcopyright} 2015 2018 Maximilian Hochmair.",
year = "2018",
month = nov,
doi = "10.2217/fon-2018-0711",
language = "English (US)",
volume = "14",
pages = "2861--2874",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "27",
}
